Nan Zheng

4PUBLICATIONS
56CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsFlight dynamics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jul 01, 2025
FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation.

Ashley C Woods, E Dianne Pulte, Xin Wang

|Oct 16, 2024
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma.

Andrea C Baines, Bindu Kanapuru, Jay Zhao

|Aug 01, 2024
FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation.

Gulsum E Pamuk, Edwin C Y Chow, Alexei C Ionan

|Sep 16, 2022
FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.

Elizabeth S Duke, Liza Stapleford, Nicole Drezner

Pageof 1

Frequent Collaborators

3 joint publications

Marc R Theoret

2 joint publications

R Angelo de Claro

2 joint publications

Jonathon Vallejo

2 joint publications

Brenda J Gehrke